Lupin launches Rufinamide Tablets USP in the United States

Lupin launches Rufinamide Tablets USP in the United States

by admin- Monday, December 5th, 2022 03:23:07 PM

Global pharma foremost Lupin launched Rufinamide Tablets USP, 200 mg and 400 mg, to marketplace a time-honored equivalent of Banzel Tablets, 200 mg and 400 mg, of Eisai Inc.

Rufinamide Tablets (RLD Banzel) had envisioned annual income of USD 138 million inside the US.

News Updates